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Background: It is known that the systems of pediatric diabetes care differ
across the member states of the European Union (EU). The aim of this project
was to characterize some of the main differences among the national systems.
Methods: Data were collected using two questionnaires. The first one was
distributed among leading centers of pediatric diabetes (one per country) with
the aim of establishing an overview of the systems, national policies, quality
control (QC) and financing of pediatric diabetes care. Responses were received
from all 27 EU countries. The second questionnaire was widely disseminated
among all 354 International Society for Pediatric and Adolescent Diabetes
members with a domicile in an EU country; it included questions related to
individual pediatric diabetes centers. A total of 108 datasets were collected
and processed from healthcare professionals who were treating more than
29 000 children and adolescents with diabetes. Data on the reimbursement
policies were verified by representatives of the pharmaceutical and medical
device companies.
Results: The collected data reflect the situation in 2009. There was a notable
heterogeneity among the systems for provision of pediatric diabetes care
across the EU. Only 20/27 EU countries had a pediatric diabetes register.
Nineteen countries had officially recognized centers for pediatric diabetes, but
only nine of them had defined criteria for becoming such a center. A system
for QC of pediatric diabetes at the national level was reported in 7/26
countries. Reimbursement for treatment varied significantly across the EU,
potentially causing inequalities in access to modern technologies.
Conclusions: The collected data help develop strategies toward improving
equity and access to modern pediatric diabetes care across Europe.
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Diabetic children in most European countries benefit
from advanced diabetes care and education. Unlike in
many other regions of the world, the access is generally
not limited by individual social or economic status, by
excessive distances to the healthcare providers or by
insufficient numbers of adequately trained healthcare
professionals. Despite this favorable situation, the
outcomes of pediatric diabetes care in Europe are
considerably heterogeneous, as previously indicated
by the Hvidoere study group (1). In their report
comparing selected indicators among 21 pediatric
diabetes centers from 17 European countries (2),
the average glycosylated hemoglobin (HbA1c) level
of the centers’ patients significantly varied from 7.4
to 9.2%, whereas the centers did not differ in the
frequency of hypoglycemia or diabetic ketoacidosis.
Most importantly, the ranking of the centers was
remarkably stable over time. The authors concluded
that some of the centers were able to implement
different treatment regimes more successfully than
others. In a later study by the Hvidoere group
(3), Swift et al. demonstrated that the therapeutic
targets (i.e., the ideal and acceptable HbA1c values as
perceived by the parents and adolescents) could explain
a considerable proportion of the HbA1c variation
among the centers.
The profound differences in average HbA1c levels,
one of the major outcome indicators, and the different
therapeutic targets set at different centers, may point to
a significant heterogeneity in the systems of education
and care provided to the diabetic children and their
families. The underlying reasons for these variations
are presently unknown. Comprehensive assessment of
current options in the provision of pediatric diabetes
care may help in delineating strategies toward its
improvement - including determining the minimum
internationally accepted standards and establishing
internationally recognized centers.
The aim of the present report was to assess the
heterogeneity in the pediatric diabetes care systems in
the member states of the European Union (EU) using
data obtained from leading health professionals.
Materials and methods
The data were collected using a questionnaire survey
among representatives of diabetes care from every
EU member state. The survey was done within the
framework of the SWEET project (described in the
Editorial, pages 1–4).
Two sets of structured questionnaires were utilized
for data collection. The first questionnaire, concerning
the current status of diabetes care in the EU states,
was sent to the heads of the leading pediatric diabetes
centers in each of the 27 EU member states. These
centers (one per country) were identified on the basis
of either scientific or clinical achievements or on the
basis of a previous collaboration with the SWEET co-
ordinators. This 15-page questionnaire was designed
to collect data on the system of pediatric diabetes care,
national policy frameworks regarding diabetes care,
the quality control (QC) of pediatric diabetes care and
its financing.
The second questionnaire (shorter, five pages) was
widely disseminated among European members of the
International Society for Pediatric and Adolescent
Diabetes (ISPAD) using its public address list. All
members with a domicile in an EU country were e-
mailed a request for help along with this questionnaire.
It collected information related to individual pediatric
diabetes centers, particularly information on their
personnel, practices and attitudes. In order tomaintain
consistency, the questions from this second (shorter,
five pages) questionnaire were also included in the first
(longer) questionnaire.
The questionnaires were implemented using the
Adobe LiveCycle Designer as active pdf documents.
They were distributed among the potential recipients
andwere collected using the built-in e-mail connectivity
function. The recipients were repeatedly reminded if
they failed to return the questionnaire in due time
and were encouraged to identify other diabetologists if
they did not feel competent to answer. There were up
to three reminders for the 15-page questionnaire; all 27
national representatives provided us with the requested
data set. The shorter five-page questionnaire that had
been sent to 354 European ISPAD members required
one reminder and was received from 107 (30.2%) of
the addressees. The collected data were then processed
using a set of Perl 5.10 scripts and analyzed in the Stata
9.0 statistical software and Microsoft Excel.
The collected data reflect the situation in 2009,
with later updates on the reimbursement of treatment
modalities provided courtesy of the representatives
of major manufacturers of insulin, glucometers,
insulin pumps and continuous glucose monitoring
(CGM) (Novo Nordisk, Bagsvaerd, Denmark; Eli
Lilly, Indianapolis, IN, USA; Bayer AG, Leverkusen,
Germany; Johnson & Johnson, New Brunswick, NJ,
USA; Roche, Basel, Switzerland; Dexcom, San Diego,
CA, USA;Medtronic, Fridley, MN, USA). These data
on reimbursement reflect the situation as of November
2010.
Results
Organization of care and education
The overview of the systems of diabetes education
and care is presented in Table 1. Selected data on the
diabetes care systems are now available at the SWEET
project website, along with an on-line comparison tool
(Fig. 2).
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Table 1. Characteristics of the diabetes care systems in the European Union countries
Item Options Countries, n of 27
Pediatric diabetes register (incidence register) •No diabetes register 7
•Operative register or registers 20
Scope
•National register 13
•Local or regional register(s) 7
EURODIAB member
•Yes 16
•No 4
Surveillance of mortality data •Not available 11
•Prospectively recorded 5
•Retrospective survey 9
•Not answered 2
Patient organizations for children with diabetes* •Exclusively pediatric 14
•Common with adults 12
•not established/not answered 1
Professional diabetes organization •Operative 26
•Not established/not answered 1
Centers for pediatric diabetes (officially recognized) •Non-existent 8
•Exist 19
Status of the center is
•Permanent 12
•Pending to reapplication 7
Status rendered by
•Ministry of Health 13/19
•Diabetes society 6/19
•Health insurance provider 4/19
•Other authority 2/19
Criteria for becoming a center defined
•Defined 9
•Not defined 10
Participation of a center in a QC† program is
•Mandatory 7
•Voluntary/QC not available 12
Quality control system in pediatric diabetes‡ •Non-existent 18
•Exists 9
Organized at the level
•National 7
•One or two centers§ 2
Indicators collected
•Glycosylated hemoglobin 9
•Diabetic ketoacidosis, frequency 9
•Severe hypoglycemia, frequency 7
•Growth data 6
•Quality of life 0
•Microalbuminuria 6
Education of diabetic patients •The content is determined by a nation-wide
plan of diabetes education
4
•The content is determined by individual centers 23
Standards of care Existence of national standard criteria for
pediatric diabetes control
•Yes 18
•No 9
If not, are criteria for adults used?
•Yes 1/9
•Partly 5/9
•Not stated 3/9
Guidelines for complications screening •Not existent 11
•Yes 16
Are they ISPAD compliant?
•Completely 3/16
•In most instances 11/16
•In part 2/16
*A list of patient organizations, professional diabetes organizations and their web addresses is given in the Table S1.
†QC, quality control.
‡Specifications of the QC systems are shown in Table 2.
§In small countries, the QC is a mutual data exchange between diabetes centers or a data audit.
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Limited: Estonia compares the only two centers in the country, Slovenia has only one center 
yes
no
not included
limited
Fig. 1. EU countries with implemented quality control systems.
At least one incidence register was operating in
20/27 countries; 16 of these registers were members
of the EURODIAB initiative, therefore, those data
were included in the last report (4). Seven countries
(Bulgaria, Cyprus, Estonia, France, Greece, The
Netherlands, and Portugal) reported that there was
no operative pediatric diabetes register, whereas
France reported having several regional registers
under development. Mortality data were prospectively
collected only in Great Britain, Hungary, Lithuania,
Slovakia, and Slovenia.
The patient and professional organizations are listed
in Table S1. Of the patient organizations, 14/26 were
dedicated to childhood diabetes only, whereas 12/26
were shared with adults.
Officially recognized centers for pediatric diabetes
existed in 19/27 countries. The authorities rendering the
status of the centers differed among countries, and the
powers and responsibilities were often shared among
institutions. The most frequently involved authority
was the Ministry of Health (13/19 countries). The
participation of each center in a QC program was
mandatory in 7 of these 19 countries.
Systems for QC in pediatric diabetes care existed
in 9 of the 27 countries (Austria, Belgium, Germany,
Denmark, Estonia, Finland, Great Britain, Slovenia,
and Sweden, Fig. 1) and differed widely in their
coverage, the set of indicators collected and their
feedback to the participants (Table 2). All systems
collected data on the glycosylated hemoglobin levels
and the frequency of diabetic ketoacidosis. None of the
systems collected data on the quality of life.
Some countries had centrally determined standards
for the content of diabetes education (France, Slovakia,
Slovenia, and Sweden), and 18/27 countries also
had national standard criteria for pediatric diabetes
control. Of those that lacked these criteria, six used
the criteria for adults, either completely or in part.
Published guidelines for the screening of complications
existed in 16/27 countries, and most were compliant
with those issued by the ISPAD (5).
Responsibilities of the diabetes care providers
To learn about the system for sharing responsibility
in diabetes care, we asked participants to rate on
a 5-point scale from 0 (never) to 4 (always), the
role of healthcare providers in five common tasks
in diabetes care: prescription of insulin, prescription
of glucometers and strips, provision of education,
prescription of insulin pumps, and provision of long-
term follow-up, including complications screening. The
respondents were asked to rate the roles of pediatric
diabetologists, diabetologists for adults, pediatricians
and general practitioners. The distribution of the sums
of the ratings then was used as indicator for the
involvement of the different specialists in diabetes care.
In most countries, pediatric diabetes care was almost
exclusively in the hands of the pediatric diabetologists
with little or no contribution by the diabetologists
for adults (Austria, Bulgaria, Germany, Hungary,
Italy, Estonia, Greece, Lithuania, Luxembourg,
Poland, Slovakia, Slovenia, Spain, Sweden, and the
Czech Republic). Other models involved a stronger
contribution of the pediatricians (Finland, France,
Ireland, and theNetherlands), the general practitioners
(Great Britain and Lithuania) or the diabetologists
for adults (Portugal, Denmark, and Belgium). In
Romania, pediatric and adult diabetologists, as well
as pediatricians, were equally involved in pediatric
diabetes care.
Reimbursement for diabetes care
Although human recombinant insulin was covered
in all 27 EU countries (with 95% or higher
reimbursement), three countries did not cover insulin
analogues or the cost to the patient was >5% of the
price. Insulin penswere reimbursed by health insurance
in 13/27 countries, whereas in the others, the costs were
covered by the pharmaceutical industry.
Personal glucometers were reimbursed or given for
free in all except three countries (Estonia, Latvia, and
Malta). The limits for reimbursement of glucometer
strips varied widely, with criteria differing not only
among but also within countries (data not shown). In
general, strips for four daily measurements seemed to
be covered in all countries.
CGM devices were reimbursed in 7/27 countries,
with various restrictions, ranging from specific patient
8 Pediatric Diabetes 2012: 13 (Suppl. 16): 5–14
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A screenshot comparing parameters of pediatric diabetes care among two EU countries 
(left and right column); http://sweet-project.eu/index.php/country-reports
Fig. 2. The web-based tool for comparison of parameters of the pediatric diabetes care systems.
indications to maximum numbers of sensors per
patient. Severe hypoglycemia was one of the most
commonly mentioned indications.
Insulin pumps were fully reimbursed without limits
in four countries, whereas most countries applied cer-
tain restrictions. Four countries had no reimbursement
for pumps at the time of the study (Bulgaria, Lithuania,
Latvia, and Romania), and a strict national quota
of 100 pumps reimbursed per year for children and
adults was applied in Portugal. The restrictions varied
substantially, being based either on strictly medical
indication criteria, on qualification of the prescribing
physician, on local funding constraints or on admin-
istratively regulated waiting times/prior authorization.
The differences among systems for reimbursing con-
sumables for pumps were also complex; whereas some
national systems fully reimbursed these consumables,
others required co-payments from the patients, covered
only limited number of sets per month, or required
prior administrative approval (data not shown).
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There was full reimbursement for diabetes education
in 11/27 countries. In seven other countries, no separate
reimbursements for educationwere provided (Bulgaria,
Greece, Hungary, Lithuania, Poland, Portugal, and
Romania). The remaining nine countries applied limits;
most often these were defined by frequency (from
once in a lifetime to four sessions each year) or
setting (reimbursed only if provided to an inpatient).
Of note, major differences in the provider payment
were reported across the EU (8-29 EUR per education
session).
Individual diabetes centers
The 354 ISPAD members with a European domicile
returned 107 (30.2%) questionnaires on the diabetes
center/practice where they worked. These centers took
care of 29 459 patients in total, with a median number
of patients of 224. There were 74 university/teaching
hospital centers (average size of 320 patients) and 33
centers from other types of hospitals (168 patients on
average). Education was provided in 84% of the centers
using a plan, which was mostly devised locally. QCwas
implemented in 68% of the responding centers, mostly
those from Germany, Austria, Belgium, Great Britain,
Belgium, Sweden, and the Netherlands.
The characteristics of staffing in these centers,
stratified by the quartiles of the number of patients, are
presented in Table 3. Although the response rate was
low and the distribution may have been skewed, there
are indices that the increasing size of the center brought
about an increased likelihood of employing specialist
nurses, educators, and psychologists. Moreover, the
non-university centers had a more proportional
relationship between the number of physicians and
the number of patients as compared to the university
hospitals (data not shown).
Discussion
Our study describes selected aspects of the provision
of pediatric diabetes care in the EU member states and
illustrates how extremely heterogeneous the systems
are. InmostEUcountries, the systems reflect a dynamic
balance between the availability of new (potentially
more costly) treatment modalities, and the limited
financial and human resources. The purpose of this
study was to provide baseline data on the status
of care for the SWEET project. This project aims
to create a network of centers of excellence that
would ensure a stable minimum level of state-of-the-
art treatment offered across the whole EU, irrespective
of the national borders. The data may thus help to
identify the strong and weak aspects of the national
systems.
Comparison to previous studies
There were several previous projects with aims related
to the subject of our survey. The ‘EUDIP’ (Euro-
pean Diabetes Indicator Project) project identified a
set of indicators (core and secondary process/outcome)
offering appropriate surveillance of diabetes melli-
tus within the EU. The ‘EUCID’ (European Core
Indicators in Diabetes) project piloted this set of
indicators in 19 EU countries (the missing coun-
tries were Bulgaria, Baltic states, Malta, Hungary,
the Czech Republic, and Slovakia, but Turkey was
included). As shown in its final report (available
from http://ec.europa.eu/eahc/projects/linkedocument/
sanco/2005/2005109_1_en.pdf, accessed 21 June 2011),
some of the indicators were very difficult to col-
lect, and six countries submitted fewer than 12
of the proposed 36 indicators. Moreover, most
indicators were available only from sources that
were limited considerably by geography or by
time and, therefore, were not representative of the
whole population. Another project collecting indi-
cators relevant to diabetes care was the B.I.R.O.
(http://www.eubirod.eu/academy/monograph/ mono-
graph.html, accessed 21 June 2011). It aimed to
standardize information exchange in diabetes. Their
approach was novel in their definition of regions as the
units of analysis (reflecting the difficulties of collect-
ing nation-wide data) and in an elaborate electronic
transfer of data and statistics. However, it appears
Table 3. Staffing of respondents’ diabetes centers and clinics and its relation to the number of patients treated
Quartile of
the size of the
center (patients)
Physicians
involved in
the care
Centers
having diabetic
nurse (%)
FTE
diabetic
nurse
Centers
having an
educator (%)
FTE
educator
Centers
having a
psychologist (%)
1 (<129) 1.9 80 0.9 20 1.1 52
2 (130–224) 2.5 93 1.6 36 1.4 86
3 (225–349) 3.1 85 1.9 37 1.8 67
4 (350+) 4.7 100 2.5 46 2.1 88
Average 3.1 90 1.7 35 1.7 74
Values are proportions or an average of the centers in the respective quartile. FTE indicates appointment in full-time
equivalents.
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that their representation of pediatric data was very
limited.
This work did not aim at defining an indicator
set; we identified readily available information on
the national systems of care that would be useful
for the other work packages of the SWEET project.
Our study has several known limitations. The primary
limitation of the study was that the questionnaire on
the diabetes care system was sent to only one person
per country. In addition, the accuracy of provided
data was verified only for reimbursement by using data
from industry. Also, our questionnaire intentionally
ignored the internal structure of the healthcare systems
that may differ between administrative units within the
country (federal states, counties, etc.).
Registers and QC
The knowledge of diabetes incidence and its trendsmay
help in the allocation of realistic resources, material
and human, needed to cope with the demands of
the future patient load. The lack of any pediatric
register in seven countries might affect the ability of
their authorities to effectively meet the needs of future
pediatric patients. Clearly, authorities from countries
without diabetes registers will have to find other
ways to estimate the future number of children with
diabetes, including retrospective assessment of number
of patients. Interestingly, a recent report from Canada
indicates that the administrative data (hospitalizations,
outpatient visits, etc.) may be surprisingly accurate for
assessing the true number of diabetic patients (6).
Conclusions from the Hvidoere study indicate that
a proper setting and a knowledge of therapeutic
targets help to improve diabetes management (3).
This may highlight the need for nation-wide plans for
diabetes education (now existing in 4 of 27 countries)
and especially the need for wide implementation
of standard criteria for diabetes control (currently
specific pediatric criteria exist in 18 of 27 countries).
Conceivably, the activities of patient organizations
may influence the perception of the therapeutic goals,
yet our study design did not allow for assessment of
such effects.
QC systemsmay be evenmore important in ensuring
adequate pediatric diabetes care. We identified eight
QC systems operating in nine countries. Their scope
and range varied widely. The glycosylated hemoglobin,
an evidence-based outcome indicator reinforced by
the results of the DCCT study (7), was included in
all QC systems. It was usually collected along with
other outcome data (frequency of hypoglycemia,
diabetic ketoacidosis, and hospitalizations) or process
data (assessment of hypertension, screening for
microalbuminuria, or autoimmune complications,
etc.). The currently running QC systems in the EU
countries varied widely in the extent of collected data,
the coverage of the population, and the published
results. Probably the most extensive system was
operating in Germany and Austria; their DPV
(diabetes data acquisition system for prospective
surveillance) covered up to 80% of all existing pediatric
and adolescent patients [over 27 000 individuals in
2005 (8)], collecting and processing a wide spectrum
of data from every diabetic patient. Another large
QC system was being run in the UK. The National
Diabetes Audit, whose last pediatric report for
England and Wales was published for 2007–2008
(http://www.ic.nhs.uk/webfiles/Services/NCASP/
audits%20and%20reports/NDA_Paediatric_Report_
2008_2009.pdf, accessed 21 June 2011) identified 13 021
children; yet, the completeness significantly varied
both with respect to the coverage of the units providing
diabetes care (100% in Wales vs. 40% in England)
and of the submitted data. Sweden had a pediatric
diabetes quality register called SWEDIABKIDS (9)
that contained data from 7660 patients (Annual
Report at www.ndr.nu/NDR2/Documents/NDR-
Child/AnnualReport-2010.pdf, accessed 21 June
2011); this is a 100% coverage of children with diabetes
in the population (G. Forsander, personal communi-
cation). Interestingly, the above-mentioned systems
used calculations to harmonize the glycosylated
hemoglobin values to testing performed in different
laboratories by different methods. The QC system
of the Danish Childhood Diabetes Registry was the
only one that collected representative samples for
centralized testing of HbA1c. It covered all pediatric
diabetes centers in Denmark (10).
This report cannot answer whether the existence
of a QC system improves diabetes outcomes. Several
papers have indicated that the levels of glycosylated
hemoglobin decrease over time as QC systems are
implemented [e.g., (2, 8, 10)], but the reason is
unknown. Conceivably, the question on the utility
of QC in improving metabolic control may be viewed
as a ‘soft’ analogy to the measurement problems of
quantummechanics; an organized studymeasuring the
glycosylated hemoglobin in a cohort constitutes per se
a mighty stimulus towards improvement in the care.
Any organizedmeasurement, or the doctor’s awareness
of being assessed, is itself a kind of intervention.
Regardless of its direct effect on the glycosylated
hemoglobin levels of patients, a QC system helps a
diabetes center keep track of its performance metrics,
including the glucose control of its patients, the
incidence of hypoglycemia and diabetic ketoacidosis
among its patients, its ability to detect and manage
diabetes complications, and other process and outcome
indicators. Although the organization of a QC system
may incur significant costs, any improvement in the
glycosylated hemoglobin towards a therapeutic target
12 Pediatric Diabetes 2012: 13 (Suppl. 16): 5–14
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may lead to significant societal financial savings, as
shown by a health-economic study from the USA (11).
Despite the differences between the US and EU in the
financing of health services, this reduction in costs may
still be very attractive. A German study had pointed
in a similar direction, indicating that an increased
glycosylated hemoglobin level was an independent
predictor of higher total costs for pediatric diabetes
care (12).
Access to modern treatment modalities
The main finding of this study is the extreme
heterogeneity of pediatric diabetes care systems across
the EU, yet at this stage, in our project, we cannot
assess whether (and to what extent) this heterogeneity
is reflected in themetabolic control or quality of life. As
very clearly exemplified by a recent publication from
the Hvidoere study (3), predictors of treatment success
are very difficult to identify, but the knowledge and
motivation of the patient may be a major contributing
factor. Little is known about the long-term effects
of modern treatment modalities on glycosylated
hemoglobin, whereas ample evidence is available on the
short- and intermediate-term beneficial effect of insulin
analogues, continuous subcutaneous insulin infusion,
and CGM. Notably in this context, the existing QC
systems donot collect quality of lifemeasures, although
this would be feasible using computerized systems
The access to modern treatment and its effective use,
including intensive education, may be dependent on
who provides the care. In most countries, the pediatric
diabetologist played the leading role, although there
are models with a stronger contribution by the
pediatricians, general practitioners, or diabetologists
for adults. Other work packages of the SWEET project
have now suggested the minimum standards of staff
needed to provide pediatric diabetes care, based upon
expert opinion.
The effective size of diabetes centers
The number of patients widely varied among centers;
moreover, we could observe a significant bias toward
university hospitals and centers from countries with
a more advanced system of QC. This study cannot
determine the minimum effective size of a center.
Nevertheless, we could observe that the centers
in the lowest quartile are less likely to have a
qualified pediatric specialist nurse, an educator or
a psychologist. Although we may assume that the
responders are biased toward the more active ISPAD
members, the overall picture of centers taking care of
almost 30 000 diabetic patients cannot be overlooked.
In our opinion, one of the prerequisites necessary for
establishing any QC system is determining a minimum
number of patients. This ‘critical mass’ of patients
enables an allocation of adequate resources, ensures
effective education, and lets the personnel achieve
proficiency by daily contacts with the patients. This
minimum number may depend on the geographical,
institutional, and organizational issues specific to the
individual countries.A taskforce of the SWEETproject
has set the minimum number of patients for the
SWEET collaborative centers to 150 [see elsewhere
in this issue (13)].
Conclusions
Despite the demonstrated significant differences
between countries in terms of the diabetes care systems,
the main challenges of diabetes care are identical
across the EU. The SWEET project should help ensure
standards in pediatric diabetes care across Europe,
taking into account local factors, and should promote
the internationally recognized criteria and procedures.
This survey may help define the current status, unravel
the previously unseen weaknesses, and identify the
strong aspects of care in the participating countries.
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